Related Experiment Video
Updated: Apr 11, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Surgical management of hepatocellular carcinoma after Fontan procedure
Steve Kwon1, Lauren Scovel1, Matthew Yeh1
11 Department of Surgery, University of Washington, Seattle, WA 98195-6410, USA ; 2 Department of Surgery, Medical University of South Carolina, Charleston, SC 29425, USA ; 3 Department of Pathology, 4 Department of Anesthesiology, 5 Department of Medicine, University of Washington, Seattle, WA 98195-6410, USA.
Abstract:
The Fontan operation has successfully prolonged the lives of patients born with single-ventricle physiology. A long-term consequence of post-Fontan elevation in systemic venous pressure and low cardiac output is chronic liver inflammation and cirrhosis, which lead to an increased risk of hepatocellular carcinoma (HCC). Surgical management of patients with post-Fontan physiology and HCC is challenging, as the requirement for adequate preload in order to sustain cardiac output conflicts with the low central venous pressure (CVP) that minimizes blood loss during hepatectomy. Consequently, liver resection is rarely performed, and most reports describe nonsurgical treatments for locoregional control of the tumors in these patients. Here, we present a multidisciplinary approach to a successful surgical resection of a HCC in a patient with Fontan physiology.

